<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>生物医药IPO on AI内参</title>
    <link>https://www.neican.ai/tags/%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AFipo/</link>
    <description>Recent content in 生物医药IPO on AI内参</description>
    <generator>Hugo</generator>
    <language>zh-cn</language>
    <lastBuildDate>Wed, 04 Feb 2026 20:40:04 +0800</lastBuildDate>
    <atom:link href="https://www.neican.ai/tags/%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AFipo/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>从硅基到血清：AI制药的“点石成金”与资本的二级进化</title>
      <link>https://www.neican.ai/insights/article-20260204204004521-0/</link>
      <pubDate>Wed, 04 Feb 2026 20:40:04 +0800</pubDate>
      <guid>https://www.neican.ai/insights/article-20260204204004521-0/</guid>
      <description>本文深度分析了AI制药领军企业英矽智能在资本市场与技术研发上的双重突破。通过拆解其商业模式与管线进展，文章揭示了人工智能如何通过“制药超级智能”重塑医药行业的效率边界，并探讨了资本在这一高增长赛道中的逻辑演进与长期价值期待。</description>
    </item>
  </channel>
</rss>
